BANDERA, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 4.936
AS - Asia 3.208
EU - Europa 2.218
SA - Sud America 500
AF - Africa 87
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 7
Totale 10.965
Nazione #
US - Stati Uniti d'America 4.617
SG - Singapore 1.107
CN - Cina 697
VN - Vietnam 488
IT - Italia 414
HK - Hong Kong 386
BR - Brasile 380
RU - Federazione Russa 375
DE - Germania 295
IE - Irlanda 259
CA - Canada 257
SE - Svezia 245
GB - Regno Unito 124
UA - Ucraina 109
FR - Francia 100
IN - India 97
BD - Bangladesh 75
FI - Finlandia 70
DK - Danimarca 54
AR - Argentina 51
ID - Indonesia 44
TR - Turchia 44
IQ - Iraq 42
KR - Corea 38
ZA - Sudafrica 38
NL - Olanda 32
ES - Italia 28
JP - Giappone 28
MX - Messico 28
AT - Austria 24
PL - Polonia 24
PK - Pakistan 23
SA - Arabia Saudita 22
BE - Belgio 15
UZ - Uzbekistan 15
PH - Filippine 14
EC - Ecuador 13
VE - Venezuela 12
CL - Cile 11
IR - Iran 11
CO - Colombia 10
MA - Marocco 9
MY - Malesia 9
AU - Australia 8
HN - Honduras 8
KE - Kenya 8
NP - Nepal 8
UY - Uruguay 8
CH - Svizzera 7
PY - Paraguay 7
AZ - Azerbaigian 6
CZ - Repubblica Ceca 6
EG - Egitto 6
ET - Etiopia 6
IL - Israele 6
JO - Giordania 6
LT - Lituania 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
EU - Europa 5
JM - Giamaica 5
LB - Libano 5
TH - Thailandia 5
TN - Tunisia 5
TW - Taiwan 5
BG - Bulgaria 4
BO - Bolivia 4
BZ - Belize 4
PE - Perù 4
PT - Portogallo 4
AL - Albania 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
HR - Croazia 3
KH - Cambogia 3
LV - Lettonia 3
ML - Mali 3
MN - Mongolia 3
OM - Oman 3
RO - Romania 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
GR - Grecia 2
MD - Moldavia 2
NG - Nigeria 2
PS - Palestinian Territory 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
DZ - Algeria 1
EE - Estonia 1
GT - Guatemala 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 10.951
Città #
Singapore 669
Ashburn 417
Hong Kong 379
Ann Arbor 375
San Jose 366
Fairfield 276
Chandler 271
Dublin 253
Houston 192
Woodbridge 186
Frankfurt am Main 181
Toronto 176
Wilmington 174
New York 161
Ho Chi Minh City 144
Dallas 142
Los Angeles 137
Milan 133
Hanoi 116
Seattle 104
Jacksonville 100
Beijing 98
Dearborn 96
Cambridge 94
Santa Clara 80
Chicago 76
Princeton 71
The Dalles 67
Hefei 65
Shanghai 51
Buffalo 50
Nanjing 42
Lauterbourg 40
Helsinki 39
Council Bluffs 37
São Paulo 35
Seoul 33
Lawrence 32
Altamura 31
Moscow 31
Ottawa 28
Rome 28
Munich 27
Tokyo 26
Fremont 21
London 21
San Diego 21
Denver 20
Florence 20
Kent 20
Nanchang 20
Boardman 19
Jakarta 19
Lachine 19
Baghdad 18
Dong Ket 18
Nuremberg 17
Rio de Janeiro 17
Amsterdam 16
Hangzhou 16
Orem 16
Brooklyn 15
Da Nang 15
Brussels 14
Warsaw 14
Guangzhou 13
Salt Lake City 13
Vienna 13
Andover 12
Chennai 12
Columbus 12
Edmonton 12
Shenyang 12
Tashkent 12
Washington 12
Brasília 11
Jeddah 11
Johannesburg 11
Redondo Beach 11
Changsha 10
Durban 10
Haiphong 10
Hebei 10
Kunming 10
Atlanta 9
Montreal 9
Quận Bình Thạnh 9
San Francisco 9
Biên Hòa 8
Boston 8
Buenos Aires 8
Bắc Ninh 8
Ha Long 8
Kiev 8
Norwalk 8
Paris 8
Poplar 8
Pune 8
Tianjin 8
Zhengzhou 8
Totale 6.854
Nome #
Microbiota in ICU, not only a gut problem 358
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 350
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 332
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 326
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 321
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 318
Brachial and central blood pressure in HIV-infected subjects 312
Strategies to limit immune-activation in HIV patients 310
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 305
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 295
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 294
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 291
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 283
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 281
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 265
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 265
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 264
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 264
Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study 248
Unmasking tuberculosis in the era of antiretroviral treatment 247
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 246
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 239
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 239
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 237
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 233
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 228
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 217
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 212
Plasma proteome investigation of COVID-19 patients with different outcomes through an untargeted label-free LC-MS/MS approach. 207
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 207
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 205
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 205
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 205
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2 200
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 187
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 186
Exogenous reinfection of tuberculosis in a low-burden area 184
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 184
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study(Front. Med., (2022), 9, (850858), 10.3389/fmed.2022.850858) 180
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 173
Characterization of SARS-CoV-2 proteins and human proteome in COVID-19 patients’ saliva and plasma: an untargeted mass spectrometry approach 172
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 171
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 170
Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 167
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 165
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 150
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 145
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 133
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 3
Totale 11.379
Categoria #
all - tutte 38.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.216


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022474 15 21 46 60 20 48 21 36 23 55 29 100
2022/2023959 102 316 74 113 40 129 10 68 65 8 23 11
2023/2024754 19 14 46 32 92 217 144 37 52 23 6 72
2024/20251.813 88 181 125 90 147 78 131 38 206 318 155 256
2025/20264.842 675 331 438 467 537 243 592 189 349 438 309 274
2026/202718 18 0 0 0 0 0 0 0 0 0 0 0
Totale 11.379